NCT04556734

Safety and Efficacy of Oral Etrasimod in Adult Participants With Moderate-to-Severe Alopecia Areata

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24-Week Study, With a 28-Week Open-Label Extension, to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Alopecia Areata

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and efficacy of etrasimod monotherapy (2 milligrams \[mg\] and 3 mg) in participants with moderate-to-severe alopecia areata (AA).

Conditions

• Alopecia Areata

Interventions

Type	Name	Description
DRUG	Etrasimod	Etrasimod 2 mg tablet by mouth, once daily
DRUG	Etrasimod	Etrasimod 3 mg (1 mg and 2 mg tablets) by mouth, once daily
DRUG	Placebo	Etrasimod matching placebo tablet by mouth, once daily

Timeline

• Start date: 2020-07-29
• Primary completion: 2023-06-07
• Completion: 2023-06-07
• First posted: 2020-09-21
• Last updated: 2024-06-26
• Results posted: 2024-06-26

Locations

42 sites across 2 countries: United States, Canada

Regulatory

• FDA-regulated drug study